A detailed history of Royal Bank Of Canada transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 11,455 shares of MRSN stock, worth $6,185. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,455
Previous 10,670 7.36%
Holding current value
$6,185
Previous $21,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.23 - $2.25 $965 - $1,766
785 Added 7.36%
11,455 $21,000
Q2 2024

Aug 14, 2024

BUY
$2.0 - $4.45 $16,244 - $36,142
8,122 Added 318.76%
10,670 $21,000
Q1 2024

Nov 05, 2024

SELL
$2.16 - $5.94 $17,543 - $48,244
-8,122 Reduced 76.12%
2,548 $11,000
Q1 2024

May 15, 2024

SELL
$2.16 - $5.94 $69,800 - $191,951
-32,315 Reduced 92.69%
2,548 $11,000
Q4 2023

Feb 14, 2024

BUY
$1.11 - $2.34 $22,125 - $46,643
19,933 Added 133.51%
34,863 $80,000
Q3 2023

Nov 14, 2023

BUY
$1.06 - $3.91 $2,171 - $8,011
2,049 Added 15.91%
14,930 $18,000
Q2 2023

Aug 14, 2023

BUY
$3.08 - $9.55 $23,583 - $73,124
7,657 Added 146.57%
12,881 $42,000
Q1 2023

May 15, 2023

SELL
$4.0 - $7.02 $31,764 - $55,745
-7,941 Reduced 60.32%
5,224 $21,000
Q4 2022

Feb 14, 2023

BUY
$5.65 - $7.86 $58,624 - $81,555
10,376 Added 372.03%
13,165 $77,000
Q3 2022

Nov 14, 2022

BUY
$4.63 - $8.0 $10,625 - $18,360
2,295 Added 464.57%
2,789 $18,000
Q2 2022

Aug 15, 2022

SELL
$2.84 - $5.0 $11,084 - $19,515
-3,903 Reduced 88.77%
494 $2,000
Q1 2022

May 16, 2022

SELL
$3.74 - $6.63 $40,021 - $70,947
-10,701 Reduced 70.88%
4,397 $18,000
Q4 2021

Feb 14, 2022

BUY
$5.48 - $9.86 $44,700 - $80,428
8,157 Added 117.52%
15,098 $94,000
Q3 2021

Nov 15, 2021

BUY
$8.56 - $14.47 $19,054 - $32,210
2,226 Added 47.21%
6,941 $66,000
Q2 2021

Aug 16, 2021

BUY
$13.28 - $18.07 $62,615 - $85,200
4,715 New
4,715 $64,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $52.5M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.